Cargando…
Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
BACKGROUND: There is considerable interest in defining the metabolic abnormalities of IDH mutant tumors to exploit for therapy. While most studies have attempted to discern function by using cell lines transduced with exogenous IDH mutant enzyme, in this study, we perform unbiased metabolomics to di...
Autores principales: | Garrett, Matthew, Sperry, Jantzen, Braas, Daniel, Yan, Weihong, Le, Thuc M., Mottahedeh, Jack, Ludwig, Kirsten, Eskin, Ascia, Qin, Yue, Levy, Rachelle, Breunig, Joshua J., Pajonk, Frank, Graeber, Thomas G., Radu, Caius G., Christofk, Heather, Prins, Robert M., Lai, Albert, Liau, Linda M., Coppola, Giovanni, Kornblum, Harley I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905129/ https://www.ncbi.nlm.nih.gov/pubmed/29692895 http://dx.doi.org/10.1186/s40170-018-0177-4 |
Ejemplares similares
-
Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022) -
Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022) -
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018) -
Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021) -
CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)